Tepnel Life Sciences PLC (AIM: TED), the international Molecular Diagnostics and Research Products & Services group announces that Dr Allan Swift has been appointed by the British In Vitro Diagnostic Regulatory Association (BIVDA) as Chairman of its Regulatory Affairs Working Group.

BIVDA represents both manufacturers and distributors who are active in the UK, irrespective of their origin. BIVDA represents some of the largest and well known diagnostic companies in the World.

The appointment began in March 2007. Allan Swift is Tepnel Life Sciences’ Group Regulatory Affairs Manager and ensures regulatory compliance of Tepnel’s products and services with all quality and regulatory agencies worldwide. Allan, a Ph.D scientist with over 80 publications, has been involved within quality and regulatory issues within the in vitro diagnostic industry for 22 years, prior to that being the scheme administrator for the UK National External Quality Assessment Schemes for Thyroid related hormones for the UK National Health Service. He is also a member of the UK National External Quality Assurance Scheme for Molecular Genetics Steering committee and a registered Laboratory Director with the New York State Department of Health.

Allan will chair the quarterly meetings of the Regulatory Affairs Working Group which consists of Regulatory Affairs professionals of all of the major UK and International in vitro diagnostic manufacturers. Currently this is the largest working group within BIVDA, with a regular attendance of 30 delegates and a membership of 50 plus.

Ben Matzilevich, CEO of Tepnel commented:

“This is a very prestigious and visible appointment for Dr Allan Swift. Diagnostics are a key part of Tepnel’s business and Allan’s in-depth experience in regulatory affairs makes him the ideal Chairman of the Regulatory Working Group at BIVDA. Having this interface with the UK and International regulatory agencies puts Tepnel at the leading edge of opinion and decision makers within the In vitro Diagnostic industry. In this new role, Allan will be at the forefront of evolving regulatory issues and as Tepnel introduces increasingly sophisticated in-vitro diagnostic products, such as QST*R, this knowledge will be invaluable.”

Doris-Ann Williams, Director General of BIVDA said “Allan has been a key member of the Regulatory Affairs Group for many years and we are delighted that he has agreed to become Chairman. I’m looking forward to working with Allan to ensure the IVD sector has input to any legislation affecting the UK operations or impacting specifically on the IVD sector”.

- Ends-

For Further Information:

Tepnel Life Sciences plc
Ben Matzilevich, CEO
Carol Smith
Tel: 0161 946 2200

Capital MS&L
Mary Clark or Halina Kukula
Tel: +44 20 7307 5330
Email: mary.clark@capitalmsl.com


Notes to Editors

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with 195 employees. TLS provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The company’s strategy has been to identify high growth niche opportunities within these multi-billion pound markets. TLS focuses on these niche opportunities with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments.

About The British In Vitro Diagnostics Association (BIVDA)

The British In Vitro Diagnostics Association (BIVDA) is the national trade association for companies with major involvement and interest in the In Vitro Diagnostics (IVD) industry. BIVDA represents both manufacturers and distributors who are active in the UK. It is not just an association of UK diagnostic companies, all IVD companies, irrespective of their national origin, are eligible to become members of BIVDA. As well as providing regulatory support for its members, BIVDA pursues a strategy of raising the awareness of the clinical and cost utility of diagnostics in the provision of effective healthcare in the UK. www.BIVDA.co.uk